Semaglutide and tirzepatide are the two most talked-about weight loss medications in the world right now. Both are FDA-approved. Both produce significant, clinically meaningful weight loss. Both are injectable peptides that you take once a week.
But they're not the same drug. They work through different mechanisms, have different clinical trial results, and come at different price points. Here's what you need to know to have an informed conversation with your physician.
How They Work: The Mechanism Difference
Semaglutide: GLP-1 receptor agonist
Semaglutide mimics a hormone called GLP-1 (glucagon-like peptide-1). When you eat, your gut naturally releases GLP-1. It does three things:
- Signals your brain that you're full — reducing appetite and food intake
- Slows gastric emptying — food stays in your stomach longer, so you feel satisfied longer
- Improves insulin sensitivity — helps your body manage blood sugar more effectively
Semaglutide is a synthetic version of GLP-1 that lasts much longer than the natural hormone. One injection per week keeps these effects going continuously. Brand names: Wegovy (for weight loss) and Ozempic (for type 2 diabetes). Same molecule, different indication and dose.
Tirzepatide: Dual GIP/GLP-1 receptor agonist
Tirzepatide does everything semaglutide does — and then adds a second mechanism. It also mimics GIP (glucose-dependent insulinotropic polypeptide), another gut hormone.
GIP is involved in fat metabolism, insulin secretion, and may have direct effects on fat tissue. By activating both GIP and GLP-1 receptors, tirzepatide attacks weight through two pathways instead of one.
Think of it this way: semaglutide turns one dial. Tirzepatide turns two. Whether two dials produce meaningfully better results depends on the individual — but the clinical trial data suggests the dual mechanism may give tirzepatide an edge.
Brand names: Zepbound (for weight loss) and Mounjaro (for type 2 diabetes).
Weight Loss: What the Clinical Trials Show
This is what everyone wants to know. Here are the actual numbers from the major trials:
Semaglutide — STEP Trials
- STEP 1: 1,961 adults with obesity. Semaglutide 2.4 mg weekly vs placebo over 68 weeks. Result: 14.9% average body weight loss (vs 2.4% with placebo). Published in the New England Journal of Medicine, 2021.
- STEP 3: Combined with intensive behavioral therapy. Result: 16.0% body weight loss.
- STEP 5: Extended 2-year data. Result: 15.2% body weight loss sustained at 104 weeks.
Tirzepatide — SURMOUNT Trials
- SURMOUNT-1: 2,539 adults with obesity. Three tirzepatide doses vs placebo over 72 weeks. Results: 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) body weight loss (vs 3.1% with placebo). Published in the New England Journal of Medicine, 2022.
- SURMOUNT-2: In patients with type 2 diabetes. Result: 12.8% and 14.7% body weight loss at 10 mg and 15 mg doses.
What the numbers mean
For someone weighing 250 pounds:
- Semaglutide: approximately 37 pounds lost on average
- Tirzepatide (15 mg): approximately 52 pounds lost on average
Tirzepatide's highest dose shows roughly 5–6 percentage points more weight loss than semaglutide. That's clinically meaningful. But context matters: not everyone takes the highest dose, individual responses vary widely, and semaglutide's 15% is already a dramatic result that transforms metabolic health.
Side Effects: How They Compare
The side effect profiles are remarkably similar. Both primarily cause gastrointestinal symptoms, especially in the first 4–8 weeks as your body adjusts:
| Side Effect | Semaglutide (STEP 1) | Tirzepatide (SURMOUNT-1) |
|---|---|---|
| Nausea | 44% | 24–33% |
| Diarrhea | 30% | 18–21% |
| Constipation | 24% | 11–17% |
| Vomiting | 24% | 8–12% |
| Discontinuation due to side effects | 7% | 4–7% |
Looking at these numbers, tirzepatide may have a slight edge on GI tolerability in clinical trials. But individual experience varies. Some people tolerate semaglutide perfectly and get nauseous on tirzepatide, and vice versa. Slow dose titration — starting low and increasing gradually — is the most effective way to manage GI side effects with either drug.
Serious side effects are rare with both. The FDA has issued warnings for both regarding:
- Pancreatitis (rare)
- Gallbladder problems (uncommon)
- Thyroid C-cell tumors (seen in animals, theoretical risk in humans — contraindicated if you have personal or family history of medullary thyroid carcinoma)
Cost Comparison
| Semaglutide | Tirzepatide | |
|---|---|---|
| Brand-name (no insurance) | $800–1,350/mo | $1,000–1,600/mo |
| Compounded | $149–399/mo | $199–599/mo |
| Insurance coverage | Improving, still inconsistent | Newer, fewer plans cover |
Compounded versions are where most patients end up. The cost difference between compounded semaglutide and tirzepatide is meaningful — roughly $50–200/month more for tirzepatide depending on the dose and provider.
Whether the extra cost is worth the potentially greater weight loss is a personal calculation. If you're weighing the value, consider: 5 extra percentage points of weight loss over a year might be worth an extra $100/month to you. Or semaglutide's results might be more than sufficient for your goals.
Which Might Your Doctor Recommend?
Several factors go into this decision:
- How much weight you need to lose: For larger weight loss goals (50+ pounds), tirzepatide's greater efficacy at high doses might tip the scale. For moderate goals, semaglutide may be sufficient.
- Type 2 diabetes: Both improve blood sugar, but tirzepatide's dual mechanism may offer additional metabolic benefits. If you have diabetes, this could factor into the decision.
- Budget: If cost is a major consideration, semaglutide is more affordable — and its results are still impressive by any clinical standard.
- GI sensitivity: If you've tried one and had intolerable side effects, switching to the other sometimes helps since they have different receptor profiles.
- Previous experience: If you've already tried semaglutide and hit a plateau, tirzepatide's additional mechanism might help break through. And vice versa.
The Bottom Line
Both are effective, evidence-based treatments for weight management. Tirzepatide has a slight edge on weight loss numbers in clinical trials. Semaglutide has a longer track record, wider insurance coverage, and lower cost. Both have similar safety profiles.
There's no wrong choice between two medications that both produce 15–20% body weight loss. The "right" one depends on your goals, your health profile, your budget, and how your body responds. That's exactly what a physician consultation is for — matching you to the treatment that gives you the best chance of success.